Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Biotech/Pharma Business
-
By Christopher P. Singer — In April 7, 2008 press releases from Novartis AG and Alcon Inc., the companies announced that Novartis has reached an agreement with Nestlé S.A. which provides Novartis with the right to acquire majority ownership of Alcon Inc. Nestlé currently owns 77% of the outstanding shares of Alcon. The…
-
By Donald Zuhn — In 2007, patent reform and biologics legislation became front burner issues. Not surprisingly, this did not escape the notice of many biotech and pharmaceutical companies, and for the past few months we have been paying close attention to reports concerning the lobbying efforts of such companies. We have already…
-
By Christopher P. Singer — Ocean Tomo will be holding its Live IP auction this spring at the Ritz-Carlton in San Francisco on April 1-2, 2008. The two day program is divided into two separate tracks, with one track titled "Leveraging IP for Investors" and the other titled "Corporate IP Strategies." The scheduled…
-
By Christopher P. Singer — IpAuctions, Inc. recently announced that it will seek to sell U.S. Patent No. 6,645,525, which relates to drug delivery technology. The patent is titled "Ionically Formulated Biomolecule Microcarriers," and is assigned to Sedum Laboratories, Inc. The technology, called "Bi-Acervation" which can encapsulate, stabilize, and provide sustained release of…
-
By Jason Derry — Pfizer Inc. has announced that it has an agreement in place to acquire Encysive Pharmaceuticals Inc. for about $195 million. Encysive is a biotechnology company that has a product currently marketed in the European Union, and several other foreign markets, for treating pulmonary arterial hypertension. The product, THELIN (sitaxsentan…
-
By Baltazar Gomez — AstraZeneca PLC announced last Thursday that it was spinning off a portion of its gastrointestinal research operations into new biotech company called Albireo. Albireo will be financed by a syndicate including Nomura Phase4 Ventures, TVM Capital, and Scottish Widows Investment Partnership. AstraZeneca will keep a significant minority stake in…
-
By Donald Zuhn — Roche announced today that it had signed a definitive merger agreement with Ventana Medical Systems. Under the terms of the agreement, Roche will increase its tender offer to $89.50 per share, or approximately $3.4 billion, and Ventana’s Board of Directors will recommend that Ventana’s shareholders tender their shares to…
-
By Christopher P. Singer — IpAuctions, Inc. has announced that it will be holding a ten day auction of intellectual property relating to bioscience and medical technologies from February 26 to March 5, 2008. The online auction firm is targeting general IP and patents particularly in the fields of cancer therapeutics and diagnostics,…
-
By Robert Dailey — ActivBiotics announced last week that it is auctioning off substantially all of its assets following the failed clinical trial of its cardiovascular drug Rifalazil. Rifalazil, a bactericidal anti-chlamidial agent, had been placed on the FDA’s Fast Track just one year ago. The drug had shown initial promise as a…
-
By Donald Zuhn — Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. announced today that the companies have entered into a merger agreement. Precision Therapeutics, Inc. is a privately-owned life sciences company based in Pittsburgh, PA that focuses on the development and commercialization of tests for use in individualizing cancer therapy. Oracle Healthcare…
Patent Docs 